Apyx Medical Corp (APYX) Form 8-K — Aug 6, 2026

$APYXForm 8-KItems 2.02, 9.01Filed Aug 6, 2026, 4:09 PM ET0001437749-26-026262Original filing

Apyx Medical reported second quarter 2026 revenue of $13.9 million, up 22% year over year, driven by 28% growth in the Surgical Aesthetics segment to $12.4 million on AYON sales, international generator sales, and single-use handpiece volume. OEM revenue declined 12% to approximately $1.5 million. Net loss attributable to stockholders narrowed to $3.2 million, or $0.07 per share, from $3.8 million, or $0.09 per share, a year ago, and Adjusted EBITDA loss improved to $0.7 million from $2.0 million. Gross margin expanded to 63.9% from 62.3% despite tariff pressure.

Key figures

Revenue: $13.9 million
Guidance: FY2026 total revenue of $59.0-$60.0 million (vs $52.8 million in FY2025); Surgical Aesthetics revenue $54.0-$55.0 million; OEM revenue ~$5.0 million; operating expenses below $45.0 million
Net Income: -$3.2 million (net loss attributable to stockholders)
Total Debt: $35.3 million long-term debt (net of discounts and issuance costs)
Revenue Yoy: +22.1%
Total Assets: $61.1 million
Cash Position: $27.6 million
Shares Outstanding: 42116330
Cash runway: management expects cash through 2027
Fda clearance: expanded 510(k) clearance for AYON Body Contouring System to include power liposuction; initial commercial shipments June 2026
Oem revenue q2: $1.5 million (-12.0%)
Gross margin q2: 63.9% vs 62.3% prior year
Gross profit q2: $8.9 million (+25%)
Six month revenue: $26.4 million (+26.8%)
Operating cash use q2: $3.5 million used vs $1.2 million used in Q2 2025
Operating expenses q2: $10.7 million vs $9.7 million prior year
Adjusted ebitda loss q2: $0.7 million vs $2.0 million loss in Q2 2025
Surgical aesthetics revenue q2: $12.4 million (+28.1%)
Six month net loss attributable to stockholders: $5.4 million (-$0.12 per share)

Price after filing

1 day: -3.3%7 days: -29.0%30 days: -28.7%

Close on the filing date to close N calendar days later (from $4.28). Historical, not a forecast.

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.